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1. Introduction
Cyclic AMP Response Element Binding (CREB) protein is a member of the CREB/ATF
(Activating Transcription Factor) family of transcription factors playing an important role in
the nuclear responses to a variety of external signals that lead to proliferation, differentiation,
apoptosis and survival. Other authors’ evidences have highlighted a critical role of CREB in
the regulation of normal haematopoiesis and leukemogenesis due to the interaction with target
genes crucially involved in the cell cycle machinery. Recent findings of our research group
have demonstrated that CREB and ATF-1 phosphorylation levels are related to a different
sensitivity of T leukaemia cell clones to the cytotoxic action of TNF-related apoptosis inducing
ligand (TRAIL) and that low dose radiation treatment of erythroleukaemia cells (K562) can
trigger CREB activation and deliver a survival signal. Since one fundamental problem of most
malignancies, including those of haematological origin, is the development of multiple
mechanisms of resistance, which progressively reduce or suppress the therapeutic efficacy of
anticancer treatment, the early identification of biological markers of responsiveness/unre‐
sponsiveness and the follow-up of individual response are highly desirable to adjust thera‐
peutic treatments. In light of all these considerations and of the complex molecular interactions
involving CREB/ATF family members, the present chapter is aimed at revising literature
focusing, in particular, on the involvement of CREB/ATF family members in leukemogenesis
and lymphomagenesis, in order to gain more insight into this matter that could result useful
to the treatment of leukaemia and lymphoma diseases.
2. CREB family members
The CREB or CREB/ATF multigenic family is composed by several nuclear transcription
factors. The prototype of this family is CREB, a 43 kDa – basic-region leucine zipper (bZIP)
© 2013 D’Auria and Di Pietro; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
transcription factor that elicits responses to a variety of extracellular signals, including stress
and growth factors, and that is involved in several cellular processes such as glucose homeo‐
stasis, proliferation, ageing and differentiation, survival and apoptosis, memory and learning
[1]. The CREB/ATF family of transcription factors includes three homologous genes: cAMP
response element binding (CREB), cAMP response element modulator (CREM), and activating
transcription factor-1 (ATF-1), whose structure domains are illustrated in a recent review [2].
These genes generate a group of highly homologous proteins that have been named after their
prototypes: CREB, CREM, and ATF-1, respectively [3].
CREB/ATF proteins were initially identified for their binding to the cyclic AMP response
element (CRE) in various gene promoters that contain the octanucleotide consensus sequence
TGACGTCA [4]. Over the years, cDNA clones encoding identical or homologous proteins have
been isolated. Up to now, at least 20 different mammalian proteins with the prefix CREB or
ATF have been characterized and grouped into subgroups on the basis of their amino acid
similarity [5, 6]. CREB/ATF family members include CREB-1 (also known as CREB), CREB-2
(recently named ATF-4), CREB-3, CREB-5, CREM, ATF-1 (also known as TREB36), ATF-2 (also
known as CRE-BP1), ATF-3, ATF-4 (previously named CREB-2), ATF-5 (also known as ATFX),
ATF-6, ATF-7 and B-ATF subgroups [7, 8]. Proteins belonging to this class represent a large
group of bZIP transcription factors containing highly divergent N-terminal domains, but
sharing a C-terminal leucine zipper domain. The basic region in the bZIP domain is rich in
basic amino acids and is responsible for specific DNA binding, while the leucine zipper region
contains leucine residues and is responsible for dimerization of the proteins by resembling a
zipper. Based on the sequence of each bZip domain, these proteins form homodimers or
heterodimers both with other members of the family and with other bZIP containing proteins
like the activator protein-1 (AP-1), C/EBP, Fos, Jun or Maf family proteins [8]. That implies the
expansion of the repertoire and different opportunities of target gene regulation that are
further increased by the alternative splice products of CREB and CREM genes that show
repressor or activator properties [5, 7]. Whereas CREB, CREM, and ATF-1 are relatively well
characterized and known to regulate gene transcription via binding to CRE sites, ATF-2, ATF-3,
and ATF-4 are structurally more distant and their functional properties remain poorly
understood. Rather than being activated by the cAMP cascade, ATF-2 is activated by c-Jun N-
terminal kinase (JNK) and can dimerize with members of the AP-1 family such as c-Jun to bind
to CRE or AP-1 sites [9, 10]. Additionally, ATF-2 homodimers and ATF-2/c-Jun heterodimers
can bind to certain CRE-like sites that are insensitive to CREB [11]. ATF-3 and ATF-4 also
dimerize with various Jun species and can shift c-Jun DNA binding site preferences from AP-1
to CRE, thereby promoting crosstalk among AP-1 and CREB protein families [9]. In addition,
ATF-4 is able to dimerize with Nrf1 (NF-E2 related factor 1) and Nrf2 (NF-E2 related factor 2)
and then interact with the antioxidant responsive element (ARE) present in the promoters of
many antioxidant genes [12]. ATF-2, ATF-3, and ATF-4 have been considered as cellular stress
response proteins [5, 13, 14] but recently they have been also involved in non-stress adapta‐
tions. In fact, extensive studies have demonstrated that ATF-3 is an adaptive response gene
that is activated by a wide variety of signals including those initiated by cytokines, genotoxic
agents or physiological stresses [15]. Interestingly, unlike other ATF family members, emerg‐
ing evidences have implicated ATF-3 in the host defence against invading pathogens and
cancer. These processes are controlled by the efficient coordination of cell responses and
genetic regulatory networks which allow this key transcription factor to modulate the
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expression of a diverse set of target genes, depending on the cell type and/or the nature of the
stimuli [16, 17].
While both CREBs and ATF-1 are ubiquitously expressed, CREMs are mainly present in
spermatids [6] and in the neuroendocrine system [18]. Interestingly, a recently published paper
on the effects of traumatic brain injury demonstrated the nuclear co-localization of CREM-1
and active caspase-3 in the ispilateral cortex of adult rats, suggesting a possible role for CREM-1
in neuronal apoptosis [19]. In a recent report of our research group on Jurkat leukaemia cells
[20], we observed a different cell compartmentalization of CREB protein in dependence of the
TRAIL dose employed and induced cytotoxicity. Indeed, both under normal or low serum
culture conditions an evident nuclear translocation of phospho-CREB was detected after 1 h
treatment only with the lower dose of TRAIL (100 ng/mL) and prevented in the presence of
PI3K/Akt and p38 mitogen-activated protein kinase (MAPK) specific inhibitors [20]. In another
model under investigation in our laboratories and represented by K562 erythroleukaemia cells
induced to differentiation [21], the nuclear localization of the active form of CREB was clearly
evident after only 1 h treatment with haemin. Interestingly, CREB positive nuclei resembled
the features of apoptotic nuclei, suggesting that CREB phosphorylation is possibly required
to determine the nuclear structural changes occurring during erythroblast maturation [21,
22]. Concerning other family members, it has been recently shown that ATF-2 is a nucleocy‐
toplasmic shuttling protein and that its subcellular localization is regulated by AP-1 dimeri‐
zation [23]. ATF-3 is ubiquitously expressed and localized in the nucleus but maintained at
low levels in the absence of cellular stresses. Instead, it is rapidly transcriptionally induced
under different conditions, among which hypoxia, DNA damage (induced by UV radiation,
ionizing radiation, etoposide), heat or cold shock, serum starvation or stimulation [13, 15].
ATF-4 is of particular interest since it has been demonstrated to translocate from the cytoplas‐
mic membrane to the nucleus in neuronal cells upon γ aminobutyric acid (GABA) receptor
activation, to be likely involved in neuronal plasticity by coupling receptor activity to gene
expression [24]. Finally, a number of immunofluorescent and cell fractionation experiments
indicate that ATF-6 is linked to the endoplasmic reticulum (ER) chaperone Bip/Crp78 and
localizes in the precursor form on the ER membrane [25]. Upon ER stress induced by prolonged
nutrient deprivation, it translocates to the Golgi where it is cleaved by resident proteases to
liberate its active N-terminal domain. In this active form it translocates to the nucleus where
it up-regulates a number of target genes involved in energy homeostasis [25].
3. CREB binding proteins
The human CREB-binding protein (CBP) and its paralogue, p300, are highly related proteins
that are well conserved amongst mammals. Due to their high degree of sequence similarity,
these two proteins are most often functionally interchangeable although they also possess
unique functions [26, 27]. CBP was initially recognized as an interaction partner for CREB
nuclear transcription factor [28], whereas p300 cDNA was cloned encoding the 300 kDa protein
known to be associated with the adenoviral protein E1A [29]. Though encoded by different
genes, CBP/p300 share several conserved regions that constitute most of their known func‐
tional domains [for details see 27]. Both CBP and p300 have originally been described as
transcriptional co-activators that bridge DNA-binding transcription factors to components of
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the basal transcriptional machinery, including the TATA-box-binding protein (TBP) [30], TFIIB
[31] and, via RNA helicase A, also RNA polymerase II [32]. Due to the huge size of over 2400
amino acids, CBP/p300 can also behave as a scaffold, bridging together a variety of cofactor
proteins at the same time and leading to the assembly of multi-competent co-activator
complexes [26, 27]. In addition, CBP/p300 interact with protein kinases such as the MAPKs
and the cyclin E-Cdk2 complex, thus mediating the phosphorylation of CBP/p300-interacting
transcription factors such as ER81 and E2F family members. Both CBP and p300 have been
found originally to possess histone acetyltransferase (HAT) activity [33]. This acetyltransferase
function has profound consequences for nucleosomal structure and the activity of transcription
factors, and thereby affects gene activity in multiple ways. In fact, it is well known that
acetylation of multiple sites in the histone tails has been directly associated with transcriptional
up-regulation, whereas de-acetylation correlates with transcriptional repression. Mechanisti‐
cally, histone acetylation promotes the accessibility of DNA to transcription protein complexes,
by facilitating the “unwiring” of the chromatin structure. During the last years, both CBP and
p300 have been regarded as protein acetyltransferases rather than only HAT since they have
shown the capacity to acetylate a number of non-histone nuclear proteins, including the
tumour suppressor protein p53, dTCF, EKLF (erythroid Kruppel-like factor), GATA-1, NF-Y
and other basal transcription factors [34, 35]. Thus, in light of the number of proteins interacting
with CBP/p300, it is not surprising to find that many physiological processes, including cell
growth, cell division, cell differentiation, cell transformation, embryogenesis and apoptosis,
are dependent on CBP/p300 function [27, 28, 34]. Moreover, the importance of CBP/p300 is
underscored by the fact that genetic alterations as well as their functional dysregulation are
strongly linked to human diseases [36, 37].
Previous studies have shown that CBP and p300 play distinct roles in haematopoiesis and
act non-redundantly in microenvironment-mediated haematopoietic regulation in spite of
their  high homology [38-40].  It  has been widely documented that  both proteins interact
with crucial transcriptional regulators in virtually all haematopoietic lineages. Intriguing‐
ly,  CBP/p300 can promote,  on one hand, normal differentiation and cell  cycle arrest  (by
cooperating with GATA-1) and, on the other hand, cell cycle progression and transforma‐
tion by cooperating with c-Myb and PU.1, an Ets family transcription factor. It is conceiv‐
able that an overexpressed oncoprotein might compete with differentiation-inducing factors
for  CBP/p300  function.  Furthermore,  during  normal  development,  CBP/p300  could
differentially  partition  among  transcriptional  regulators  with  opposing  functions,  thus
controlling the balance between proliferation and differentiation. As an example, the down-
modulation of the proto-oncoproteins PU.1 and c-Myb during the erythroleukaemia MEL
cell  line maturation might increase availability of CBP/p300 for differentiation-associated
factors such as GATA-1,  NF-E2 and EKLF. Moreover,  besides the involvement in eryth‐
roid cell lineage differentiation, CBP and, very likely, p300 target a broad range of myeloid
and lymphoid expressed transcription factors [38-40].
Because of its central role in transcription, it is not surprising that aberrations in CREBBP can
affect many tissues [17]. In humans, chromosomal translocations involving the CREBBP gene
have been observed in leukaemia and myelodysplastic syndrome [38]. Mutations of CREBBP
in the germline have been associated to the Rubinstein-Taybi syndrome (RTS), an autosomal
dominant disease characterized by mental retardation, skeletal abnormalities and a high
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propensity to develop cancer, including leukaemia [36]. Similarly, CREBBP(+/-) mice show
abnormalities in bone, haematopoietic tissues and neural tissues and an increased tendency
to develop haematological malignancies with age [41]. In earlier studies, in CREBBP(+/-) HSCs
(haematopoietic stem cells) a number of cell-intrinsic defects have been described, including
diminished HSC self-renewal and excessive myeloid differentiation [42]. The combination of
skeletal and haematopoietic defects in CREBBP(+/-) mice suggests the involvement of the bone
marrow (BM) microenvironment in the haematopoietic phenotype of these mice. One of the
genes whose transcription is directly regulated by CBP is matrix metalloproteinase 9 (MMP9)
that was reported to be a microenvironmental regulator of haematopoiesis [43]. Interestingly,
CREBBP heterozygosity in the BM microenvironment results in reduced levels of MMP9 and
soluble kit ligand (KITL) and increased expression of endothelial cell adhesion molecule 1
(ESAM1) and cadherin 5 (CDH5) on a subset of endothelial cells. In addition, it has been
reported that the loss of a single CREBBP allele is deleterious for the BM microenvironment,
leading to defective haematopoiesis. In fact, the CREBBP(+/-) microenvironment poorly
supports HSCs, promotes excessive myelopoiesis and reduces lymphopoiesis. Furthermore,
it has been reported that CREBBP(+/-) mice have reduced bone volume due to increased
osteoclastogenesis. A concomitant reduction in CFU-fibroblasts (CFU-Fs) and osteoblasts per
tissue area was also identified and likely contributes to fewer HSC niches [41]. Thus, all these
findings reveal the importance of CBP in the development and function of the BM microen‐
vironment and underscore the multiple levels at which this protein acts to regulate haemato‐
poiesis. Indeed, half of the normal complement of CREBBP, but not of EP300, in the BM
microenvironment has a deleterious effect on haematopoiesis via multiple mechanisms,
leading to the development of excessive myelopoiesis, disrupting the proper architecture of
the BM and resulting in poor maintenance of HSC number and quality.
4. CREB physiological roles and signalling pathways
CREB is a multi-functional transcriptional activator that is involved in many signalling
pathways under normal and pathologic conditions. CREB mediates its transcriptional
responses following phosphorylation at Ser133 [7] and the consequent association with the 256
kDa co-activator CBP [28] or related family members like p300 [29]. Both Ser133 phosphory‐
lation and CBP association play an essential role for gene transactivation mediated by an
octanucleotide CRE consensus sequence placed in the promoters of many cellular genes [29].
In more detail, CREB transactivation domain, that is the site able to interact with other nuclear
factors, contains a constitutive glutamine rich domain termed Q2 and an inducible domain,
termed the kinase-inducible domain (KID), regulated by cellular kinases [2]. The Q2 domain
interacts with a TATA binding protein-associated factor and is constitutively active; instead,
the KID region promotes isomerization by recruiting the co-activator factors CBP and p300 to
the gene promoters and is active only when it is phosphorylated at Ser133 by a variety of
cellular kinases. Recent studies using a genome-wide analysis showed that the number of
putative target genes for CREB is about 5000, among which immediate-early genes, including
c-FOS, AP-1/JunB and early growth response protein 1 (EGR-1) [44], as well as genes crucially
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involved in the cell cycle machinery, namely Cyclin A1 and D1 [7]. In this respect, it has been
found that Cyclin A is up-regulated in cell lines, transgenic mice and patient bone marrow that
show increased CREB levels [44]. It is still to unravel whether this occurs through a direct or
indirect mechanism. To address this issue or, in other words, to determine whether CREB
overexpression results in target gene activation through increased occupancy of binding sites
or by altering levels of Ser133 phosphorylation, several authors proposed to use chromatin
immunoprecipitation assays. Moreover, microarray analysis of potential CREB target genes
will help in understanding the downstream pathways through which CREB contributes to
normal and aberrant haematopoiesis. By interacting with its huge number of target genes
CREB plays a critical role in the regulation of various biological processes including haema‐
topoiesis, liver gluconeogenesis, pituitary gland physiology, circadian rhythm, spermatogen‐
esis, learning and memory [1, 45, 46]. Concerning haematopoiesis, CREB is a downstream
target of haematopoietic growth factor signalling activated by granulocyte-macrophage–
colony stimulating factor (GM-CSF) and interleukin-3 (IL-3), thus resulting a crucial factor for
normal myelopoiesis [44]. In addition, it appears to play a role in primary erythroblast
differentiation [47] as well as in megacaryocyte differentiation where it is activated in a MAPK-
dependent manner [48]. More recently, it has also been involved in HSC and uncommitted
progenitor proliferation and survival through its effects on cell cycle control [45, 46]. A growing
body of evidences is unravelling the role of CREB in the regulation of the immune system [49].
Indeed, several immune-related genes contain a cAMP responsive element, as in the case of
IL-2, IL-6, IL-10 and TNF-α. In monocytes and macrophages CREB exerts anti-apoptotic
survival effects. Moreover, CREB promotes normal B and T cell survival and proliferation
when it is phosphorylated in response to signalling by the B-cell receptor or different kinases
[49]. Particularly well characterized is the regulatory role that CREB plays in the nervous
system. Actually, numerous papers have demonstrated CREB involvement in promoting
neuronal survival, precursor proliferation, neurite outgrowth and neuronal differentiation in
certain neuronal populations [50], highlighting the importance of CREB signalling in learning
and memory processes in several organisms [2, 51].
In the late 1980s, it was discovered that cAMP mediates the hormonal stimulation of several
cellular processes by regulating the phosphorylation of critical proteins among which CREB
transcription factor [52]. Although it was initially identified as a target of the cAMP signalling
pathway, studies on activation of immediate-early genes revealed that CREB is a substrate for
kinases other than cAMP-dependent protein kinase A (PKA) and that various signalling routes
converge on CREB and CREM, controlling their function by modulating their phosphorylation
states [52, 53]. As above mentioned, almost all the signalling pathways that activate CREB lead
to the phosphorylation of Ser133, which is required for CREB-induced gene transcription, but
additional sites on CREB or on linked proteins can be phosphorylated exerting a modulation
of CREB activity [35]. For example, Ser133 phosphorylation primes CREB for phosphorylation
by Glycogen synthase kinase 3 (GSK-3) at Ser129. However, unlike Ser133 phosphorylation,
the physiologic consequences of Ser129 phosphorylation are not well defined, although
evidence suggests that it is also linked to CREB activation [54]. In different systems a number
of different kinases have been shown to stimulate CREB phosphorylation and several CREB
kinase candidates have been identified so far. PKA, which is activated by cAMP, is the major
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kinase that targets Ser133 in many processes [1, 3]. Other signalling molecules responsible for
CREB Ser133 phosphorylation include mitogen- and stress-activated kinase 1 (MSK-1),
extracellular signal-regulated kinase (ERK), calcium/calmodulin-dependent kinases (CaMKs),
p90 ribosomal S6 kinase (RSK), MAPKs and Akt/protein kinase B (PKB) [1, 3, 7, 55, 56]. Both
MAPK and Akt have been shown to enhance the survival of cultured cells by stimulating
CREB-dependent target gene expression [56]. CREB activity is also regulated by a family of
cytoplasmic co-activators known as transducers of regulated CREB activity (TORCs) and
including TORC1, TORC2 and TORC3. TORCs are activated by extracellular stimuli repre‐
sented by nutrients (glucose) and hormones. Once activated, they translocate into the nucleus
where they bind to the bZIP domain of CREB exerting its activation through a phospho-Ser133-
independent mechanism. All TORCs are regarded as strong activators of CREB-dependent
transcription [57].
In Fig. 1 the main factors and signalling molecules leading to CREB activation in haemato‐
poietic cells are schematically represented.
Figure 1. Schematic representation of the main factors and signalling molecules leading to CREB activation in haema‐
topoietic cells. A various array of extracellular stimuli promote CREB activation through phosphorylation or through
interaction with CREB co-activators to enhance the expression of CREB responsive genes. CREB target genes, including
Cyclin A1, are able to mediate effects on cellular proliferation, apoptosis, survival and differentiation. PLC: phospholi‐
pase-C; DAG: 1,2-diacylglycerol; PKC-ε: protein kinase C-ε.
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5. CREB family members and leukemogenesis
Recent data suggest that CREB acts as a proto-oncogene in haematopoietic cells and contributes
to the leukaemia phenotype [37, 38, 45, 46]. It has been shown anyway that CREB is able to
promote tumour formation only when other oncogenes are also activated. In fact, its overex‐
pression is not sufficient to induce acute leukaemia in vivo. This is consistent with similar
observations obtained with translocations, such as AML1-ETO (Acute Myeloid Leukaemia
Eight-Twenty-One), a chimeric protein that requires additional mutations to develop leukae‐
mia in mouse models [58]. In previous works different strategies have been delineated to
identify the oncogenes cooperating with CREB to drive leukemogenesis: one way is repre‐
sented by crossing different transgenic mice of known oncogenes such as K-RAS, MEIS 1, PML/
RARα etc. to CREB transgenic mice; another approach consists in infecting CREB transgenics
with a retrovirus such as the Molony murine leukaemia virus to insertionally activate coop‐
erating oncogenes. The latter approach has also the potential to identify novel collaborators of
CREB besides the already known CBP and p300. Identifying novel oncogenic alterations that
cause leukaemia and discovering the signalling pathways involved will be of great value to
gain a better knowledge of the disease and to lead to novel and more efficient therapeutic
measures.
Several CREB family members have been implicated in different malignant conditions. The
first malignancy to be discovered was the clear cell sarcoma of the soft tissue (CSST). In
this  solid  tumour,  the  cells  are  induced to  proliferation by an Ewing’s  Sarcoma (EWS)-
ATF-1 fusion oncoprotein derived by a  chromosomal  translocation that  fuses  the  DNA-
binding and bZip domain of ATF-1 to the EWS gene. In haematological malignancies, CREB
has been implicated in the pathogenesis of human T lymphotropic virus I (HTLV-I) related
T-cell leukaemia [59] and also associated with the genesis of follicular lymphoma, where
CREB binds to the CRE site in the promoter of translocated Bcl-2 [46]. Other leukaemia-
associated chromosomal translocations involving the CBP and p300 genes were also linked
to haematological  malignancies.  These  translocations  generally  result  in  fusion products
that  preserve  most  of  the  CBP and p300  molecules,  suggesting  that  the  disease  mecha‐
nism does not simply involve loss of function of CBP, as is the case in Rubinstein-Taybi
syndrome, but often implies an altered cofactor function (dominant positive or dominant
negative) through fusion to another molecule. The most frequent chromosomal transloca‐
tions targeting CREBBP  and EP300  have been described in specific  subtypes of  myeloid
leukaemia  and  are  represented  by  Mixed-Lineage  Leukaemia  1  (MLL)-EP300,  MLL-
CREBBP,  MOZ-CREBBP  and  MOZ-EP300  [37,  60].  Interestingly,  most  translocations
involving  CREB-related  genes  result  in  leukaemia  of  the  myeloid/monocytic  lineage,
highlighting the importance of CREB and CREB-interacting proteins in the regulation of
haematopoietic  cell  differentiation  and  proliferation  [45,  46].  Actually,  previous  work
demonstrated  that  bone  marrow  cells  from  patients  with  acute  myeloid  or  lymphoid
leukaemia expressed higher levels of CREB compared to patients not affected by leukae‐
mia  or  with  normal  bone  marrow  [60].  Moreover,  it  appears  that  an  elevated  CREB
expression is associated with an increased risk of relapse or persistent disease and decreased
event-free survival  [45].  This is  consistent with the observation that  leukaemia cell  lines
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expressing  CREB at  elevated levels  show an increased growth/proliferation  rate  in  nor‐
mal conditions and an increased survival when exposed to stress like serum starvation [61].
On the contrary, down-regulation of endogenous CREB in leukaemia cell lines by siRNA
resulted in  reduced cell  viability  [20,  45],  indicating that  CREB is  a  critical  regulator  of
growth  and  survival  in  both  myeloid  and  lymphoid  leukaemia  cells.  Unfortunately,
chromosomal  translocations  have  also  been  involved  in  drug-induced  leukaemia.  For
instance,  the  involvement  of  11q23-balanced  translocations  in  acute  leukaemia  after
treatment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being
recognized with increasing frequency. It has been shown that the gene at 11q23, involved
in all of these treatment-related leukaemias, is MLL (also called ALL1, Htrx, and HRX). In
general, the translocations occurring in these leukaemias are the same as those occurring
in de novo leukaemia [eg. t(9;11), t(11;19), and t(4;11)]. Interestingly, the t(11;16)(q23;p13.3)
has  been  cloned  and  has  been  shown  to  involve  both  MLL  and  CREBBP  [62].  Besides
chromosomal  translocations,  another  way  for  CREB  to  contribute  to  tumorigenesis  is
through the  suppression  of  cellular  genes  either  by  competing  with  or  binding  to  sites
occupied by other transcription factors or by confiscating the transcriptional machinery [63].
5.1. Acute myeloid leukaemia
Acute leukaemia derives from the clonal expansion of haematopoietic stem/progenitor cells
that have lost their ability to undergo terminal differentiation. Since transcription factors
control HSC production and differentiation, it is conceivable that disorders of the haemato‐
poietic system often involve alterations of the regulatory network of transcription factors. In
haematological malignancies transcription factors can be overexpressed, involved in chromo‐
somal translocations or become targets of somatic mutations that disrupt their normal function
[37, 60-63]. Previous studies have demonstrated that CREB is a proto-oncogene whose
overexpression promotes cellular proliferation in haematopoietic cells [1, 3]. The abnormal
proliferation and survival of myeloid cells in vitro and in vivo appears to be due to the up-
regulation of CREB target genes such as Cyclin A1 [60, 63]. Transgenic mice that overexpress
CREB in myeloid cells develop a myeloproliferative disease with splenomegaly and aberrant
myelopoiesis. However, CREB overexpressing mice do not spontaneously develop acute
myeloid leukaemia (AML) [61]. To identify genes that accelerate leukaemia in CREB transgenic
mice retroviral insertional mutagenesis has been used. The mutagenesis screen identified
several integration sites, including oncogenes Gfi1, Myb, and Ras. Among transcription factors,
Sox4 was identified with the screen as a gene that cooperates with CREB in myeloid leukemo‐
genesis by contributing to increased proliferation of haematopoietic progenitor cells [64].
Moreover, chromatin immunoprecipitation assays have demonstrated that CREB is a direct
target of Sox4. In fact, it has been shown that the transduction of CREB transgenic mouse bone
marrow cells with a Sox4 retrovirus increases survival and self-renewal of cells in vitro and
results in increased expression of CREB target genes. Consistently, leukaemia blasts from the
majority of AML patients have higher levels of CREB, phospho-CREB, and Sox4 protein
expression in the bone marrow [64]. The increase in both CREB protein and mRNA levels in
primary AML cells is possibly due to CREB gene amplification in the blast cells. Furthermore,
a higher level of CREB has been found to correlate with a less favourable prognosis and an
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increased risk of relapse and decreased event-free survival in a small cohort of AML patients
[45, 61]. Generally, AML in adults has a 20% five-year disease free survival despite treatment
with aggressive cytotoxic chemotherapy and two thirds of AML patients do not experience
significant periods of remission. Therefore, in light of its important role in the pathogenesis of
leukaemia, CREB has been indicated as a potential prognostic marker of disease progression
in AML and a molecular target for future treatment of leukaemia.
Clinical and experimental findings underline that AML is induced by numerous functionally
cooperating genetic alterations, including chromosomal translocations that lead to the
expression of fusion proteins often behaving as aberrant transcription factors. Several AML-
associated lesions target chromatin regulators like histone methyltransferases or histone
acetyltransferases, including MLL1 or CBP/p300 [65]. As already mentioned, CBP is an adapter
protein that is involved in regulating transcription and histone acetylation, through which it
is thought to contribute to an increased level of gene expression. The CBP gene was recently
identified as a partner gene in the t(8;16) that occurs in de novo acute myelomonocytic leukae‐
mia (AML-M4) and rarely in treatment-related AML [66]. The fusion gene could alter the CBP
protein so that it becomes constitutively active or, alternatively, it could modify the chromatin-
association functions of MLL gene [38, 40]. MLL and HOXB4, a member of the homeobox
domain transcription factors, have been identified as regulators of HSC maturation during
early haematopoiesis [67]. HOXB4 belongs to the HOX genes, a family of oncogenes implicated
in the pathogenesis of various human cancers and highly expressed in the majority of AML.
In a recent report Wang et al. [54] demonstrated the association of CREB and its co-activators
TORC and CBP with homeodomain protein MEIS1, a HOX DNA-binding cofactor and critical
downstream mediator of the MLL oncogenic program. This MEIS-CREB nexus is regulated by
GSK-3, a multi-functional serine/threonine kinase that impairs the proliferation and induces
the differentiation of a variety of cancers, including leukaemias, induced by MLL oncogenes.
This kinase mediates CREB activation through phosphorylation at Ser129. In fact, CREB Ser129
mutation antagonizes HOX/MEIS activity and decreases colony-forming abilities of HOX/
MEIS or MLL transformed cells. These and other similar observations provide a molecular
rationale for targeting HOX-associated transcription through GSK-3 inhibition in a subset of
leukaemias.
Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal haematopoietic
stem cell malignancies with significant morbidity and high mortality. The incidence of MDS
increases markedly with age and the disease is most prevalent in individuals who are white
and male. Because of an ageing population and an improving awareness of the disease, the
documented disease burden is expected to worsen in the near future. Due to the poor survival
of individuals with MDS, it is important to identify prognostic factors to better risk-stratify
patients for more effective treatments [68]. Genomic instability is associated with progression
of the disease so that a part of patients develops AML. It has been reported that an increased
incidence of haematological malignancies occurs in CREBBP heterozygous mice and other
authors have shown that CREBBP is one of the genes altered by chromosomal translocations
in patients suffering from therapy-related myelodysplastic syndrome [69]. Moreover, it has
been demonstrated that CREBBP(+/-) mice invariably develop myelodysplastic/myeloproli‐
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ferative neoplasm within 9-12 months of age. They are also hypersensitive to ionizing radiation
and show a marked decrease in poly(ADP-ribose) polymerase-1 activity after irradiation. In
addition, protein levels of XRCC1 (X-ray repair complementing defective repair in Chinese
hamster cells 1) and APEX1 (APEX nuclease), key components of base excision repair machi‐
nery, are reduced in un-irradiated CREBBP(+/-) cells or upon targeted knockdown of CREBBP
levels. These results provide validation of a new myelodysplastic/myeloproliferative neo‐
plasm mouse model and, more importantly, point at a defective repair of DNA damage as a
contributing factor to the pathogenesis of this currently incurable disease [46].
5.2. Acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease characterized by the
predominance of immature haematopoietic cells, in which malignant cells express phenotypes
of either T-cell or B-cell lineages [61]. ALLs account for the 25-30% of all cancer diagnoses in
children. CREB involvement in the molecular events related to in vitro and in vivo lympho‐
blastic proliferation is still little known, whereas a lot of evidences disclose a role of CREB as
a proto-oncogene in haematopoiesis and in AML. CREB can be overexpressed in the 84% of
ALL patients (73/86) at diagnosis but neither in remission nor in non-leukaemia samples [70].
By contrast, the parallel expression of the cAMP early inducible repressor (ICER), which
represses CREB activity by competing for the CRE consensus site, appears down-regulated at
diagnosis but neither in remission nor in control samples [70]. Thus, it is presumable that CREB
overexpression leads to target gene up-regulation and increase in cell proliferation and
survival that are not counteracted by the insufficient level of ICER expression. Besides this
hypothesis, Pigazzi et al. [71] have also demonstrated the co-expression of miR34b in CREB
overexpressing myeloid leukaemia cells providing new information about myeloid transfor‐
mation and therapeutic strategies. Despite the apparently good prognosis, the 15% of high
hyper-diploid (HD) childhood ALL cases relapse [72, 73]. Relapsed ALL is a leading cause of
death due to disease in young people, but the molecular mechanisms of treatment failure are
still to be elucidated. Genome-wide profiling of structural DNA alterations in ALL identified
multiple sub-microscopic somatic mutations targeting key cellular pathways and demonstrat‐
ed evolution in genetic alterations from diagnosis to relapse [74]. Many of the mutations that
have been identified concern the transcriptional co-activators CREBBP and NCOR1, the
transcription factors ERG, SPI1, TCF4 and TCF7L2, components of the Ras signalling pathway,
histone genes, genes involved in histone modification (CREBBP and CTCF) and genes target
of DNA copy number alterations [74]. The parallel analysis of an extended cohort of diagnosis-
relapsed cases and acute leukaemia cases that did not relapse showed that the 18.3% of relapsed
cases had sequence or deletion mutations of CREBBP [72, 74]. CREBBP is expressed in
leukaemia cells and normal B-cell progenitors, and the mutant CREBBP alleles are expressed
in ALL cell lines harbouring mutations. Mutations at diagnosis or acquired at relapse consist
in truncated alleles or deleterious substitutions in conserved residues of the histone acetyl‐
transferase domain, impairing histone acetylation and transcriptional regulation of CREBBP
targets, including glucocorticoid responsive genes. In mice the homozygous deletion of
CREBBP or EP300 is lethal due to developmental abnormalities whereas CREBBP(+/−) mice
show defects in B lymphoid development and an increased incidence of haematopoietic
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tumours [75]. Both CREBBP and EP300 sequence mutations have been reported in solid
tumours and, more recently, also in haematological malignancies, whereas rare EP300
mutations have been detected in an ALL cell lines and myelodysplasia [74, 76]. A lot of detected
mutations at relapse, the same identified at diagnosis in other clones, prove that mutations
confer resistance to therapy. Many identified mutations are target in transcriptional and
epigenetic regulation as a mechanism of resistance in ALL. It is worth outlining that the high
incidence of CREBBP mutations found in relapse-prone HD ALL cases discloses the possibility
of a targeted customized treatment in this genetic subgroup [73].
In our laboratory we have investigated the role of PI3K/Akt pathway and CREB family
members in a number of lymphoid and erythroleukaemia cell lines treated with chemical and
physical agents inducing cell death by apoptosis or necrosis [20, 21, 47, 77-80]. We first detected
with Western Blotting a high constitutive level of CREB phosphorylation at Ser133 in Jurkat T
cells under normal serum culture conditions [20]. Under low serum culture conditions, an early
(within 1 h) and transient increase in CREB phosphorylation was observed in response to
TRAIL treatment and reduced upon pre-treatment with LY294002 or SB253580, demonstrating
the PI3K/Akt- and p38 MAPK-dependency of this effect. Interestingly, both phospho-CREB
and phospho-ATF-1 were down-regulated in response to TRAIL treatment of normal primary
cells derived from haematopoietic precursors (HUVEC, HEMA), whereas both of them were
up-regulated in the neoplastic counterparts (K562 cell line) [20, 21]. The PI3K/Akt pathway
dependency of CREB/ATF-1 phosphorylation induced by TRAIL treatment was demonstrated
both in primary cells and in leukaemia cell lines of different origin and TRAIL sensitivity,
showing that the observed phenomenon is a general feature of TRAIL action in leukaemia [77,
80]. In addition, the observation of CREB cleavage products upon TRAIL/LY294002 combined
treatment of sensitive leukaemia cells was consistent with previous reports on other neoplastic
cell lines [81] and compatible with the TRAIL-mediated activation of the caspase cascade and
cleavage of anti-apoptotic molecules. The parallel analysis with immune fluorescence dem‐
onstrated the nuclear translocation of the phosphorylated form of CREB upon treatment with
100 ng/mL TRAIL, whereas the immune labelling was mainly detectable in the cytoplasm
compartment upon the higher more cytotoxic dose (1000 ng/mL) as shown in Fig. 2. A further
enhancement of apoptotic cell death was obtained with the use of CREB1 siRNA technology
leading us to hypothesize that CREB activation can have an important role in the complex
crosstalk among pro- and anti-apoptotic pathways in Jurkat T cells [20, 80].
5.3. Chronic myelogenous leukaemia
Chronic myelogenous leukaemia (CML) is characterized in the 85-90% of the cases by the
presence of the Philadelphia (Ph) chromosome and the BCR-ABL fusion gene. A further
5-10% of the cases display other translocations, most commonly complex variants, that in‐
volve one or more chromosomal regions in addition to bands 9q34 and 22q11, but also sim‐
ple variants that typically involve 22q11 and a chromosome other than 9q34. However,
genes that cooperate with BCR-ABL leading to acute leukaemia are not well understood nei‐
ther the role played by CREB in CML has been clarified. Preliminary observations of the
group of Kathleen Sakamoto indicate that CREB is highly expressed in blood and bone mar‐
row cells from patients with CML in chronic phase, but not in normal bone marrow cells
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[82]. The same authors previously showed that inhibition of CREB by using RNA interfer‐
ence (RNAi) technology resulted in decreased proliferation and survival of bcr-abl-express‐
ing K562 cells [45, 83], whereas other authors reported that CREB antisense oligonucleotides
were able to induce death of human leukaemia cells and bone marrow cells from patients
affected with both AML and CML [84]. A critical factor for the genesis of acute leukaemia or
acute transformation of CML appears to be the formation of fusion genes between NUP98
and members of the HOX gene family [85]. Interestingly, all the NUP98-HOX-involved fu‐
sion products exhibit dual binding ability to both CREB binding protein, a co-activator, and
histone deacetylase 1, a co-repressor, acting as both trans-activators and trans-repressors
and contributing to the genesis of acute leukaemia or acute transformation of CML [86].
 
Figure 2. a, b: Phospho-CREB localization in Jurkat T cells upon TRAIL treatment. An evident nuclear translocation
of phospho-CREB (green fluorescence) was detected upon 1 h treatment only with the lower dose of TRAIL (panel a),
whereas the labelling was located at cytoplasm level upon the higher more cytotoxic dose (panel b). Nuclei were
counterstained with 6-diamino-2-phenylindole (DAPI) (blue fluorescence). Green and blue fluorescence single emis‐
sions are overlapped in the merge panels. The insets show green fluorescence single emission. Original magnification:
40X. The figure has been adapted from [20].
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5.4. Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) originates from the abnormal accumulation of antigen-
stimulated B cells that escape normal cell death mechanisms and/or undergo increased
proliferation [87]. CLL is the most prevalent adult leukaemia in the Western world, yet no
curative treatment exists. Many studies have explored the use of family-specific cyclic
nucleotide phosphodiesterase (PDE) inhibitors in light of the potent effects of cAMP signalling
on immune system function [88, 89]. Among the 11 currently known families of cyclic
nucleotide PDEs, all but three are capable of catabolizing cAMP and at least 5 PDE families
(PDE1-4, PDE7 and PDE8) are expressed in lymphoid cells and regulated by either mitogens
or agents that induce cAMP-mediated signalling. Previous work has established that inhibition
of PDE4 is sufficient to selectively induce apoptosis in CLL cells by increasing the concentration
of cAMP [88]. In a recent paper Meyers et al. [89] examined how CLL cells differ from normal
haematopoietic cells with regard to their sensitivity to PDE4 inhibitor-mediated cAMP
accumulation, CREB phosphorylation and gene expression. Interestingly, it was discovered
that upon exposure to rolipram, a prototypical PDE4 inhibitor, cAMP intracellular levels
rapidly rose in both CLL and normal B cells, whereas no such increase was detected in T cells.
Likewise, ATF-1/CREB Ser63/133 phosphorylation was induced by rolipram in nearly all CLL
and B cells, whereas normal T cells displayed a lower response. Based on these findings and
on previous observations of a reduced basal cAMP signalling in CLL cells, the authors
suggested the involvement of specific PDE or splice isoforms in the reduced basal apoptotic
index of CLL cells [89]. Looking for etiological agents, other authors have identified a stromal
cell–derived factor-1 (SDF-1)-dependent mechanism as a microenvironmental regulatory
mechanism of CLL cell survival [90]. It is known that SDF-1 is a chemokine that plays an
important role in B-cell development. In fact, high levels of SDF-1 are produced by stromal
cells within the marrow to retain B-cell precursors in close contact with them, within the
supportive haematopoietic microenvironment [91], and to prevent their premature release into
the circulation. Upon in vitro treatment of CLL cells with synthetic SDF-1α, a rapid and
transient activation of p44/42 MAPK (ERK1/2) signalling pathway was observed and related
to CLL cell survival. Downward MAPK activation transcription-dependent and -independent
mechanisms were involved. In fact, MAPK was able to promote cell survival directly by
inactivating the pro-apoptotic BAD protein and indirectly by activating CREB, which, in turn,
is important for the transcriptional up-regulation of the anti-apoptotic BCL-2 gene [92]. Thus,
SDF-1 engages B lineage CLL cells through the stromal cell receptor CXCR4 and affects
components of the cell death machinery, leading to the noted resistance of CLL cells to
apoptosis.
5.5. Human T Lymphotropic Virus 1 (HTLV-1) related T cell leukaemia
Human T-cell leukaemia virus type-I (HTLV-1) is the first discovered human retrovirus [93].
It has been recognized as the etiological agent of an aggressive malignancy known as adult T-
cell leukaemia (ATL) as well as of the neurological syndrome TSP/HAM and of other clinical
disorders. In vitro HTLV-1 is able to infect a number of different cell types, whereas in natural
human infections it generally targets mature CD4+ helper T cells or, less frequently, CD8+ T
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cells. Although the mechanism of HTLV-1 pathogenicity is not fully understood yet, it is widely
believed that a virally encoded trans-activator protein, called Tax, is centrally involved in this
mechanism. In a recent review Azran et al. [94] provide valuable insights into the molecular
mechanisms of HTLV-1 leukemogenesis. In particular, the authors detail the signalling
pathways recruited by Tax to set infected T cells into continuous uncontrolled replication and
to destabilize their genome, enabling, thereby, accumulation of mutations that can contribute
to the leukemogenic process. Tax is able to modulate the expression of many viral genes via
the viral long terminal repeat (LTR) and cellular genes through the CREB/ATF-, AP-1-, serum
responsive factor (SRF)- and NF-κB-associated pathways, employing the CBP/p300 and p/CAF
(p300/CBP-associated factor) co-activators for achieving the full transcriptional activation
competence of each of these pathways. It is worth noting that Tax responsive elements (TxRE)
contain a centered sequence TGACG(T/A)(C/G)(T/A) that is imperfectly homologous to the
consensus cAMP responsive element (CRE; TGACGTCA). Thus, the presence of Tax is
necessary for CREB to form a stable complex with the viral CRE. In fact, by interacting with
the bZIP region of CREB, Tax enhances CREB dimerization and increases, thereby, its affinity
to CRE. In particular, it has been recently shown that CREB is the most prominent factor that
cooperates with Tax in activating HTLV-1 LTR region expression [95]. Moreover, it has been
demonstrated that while, in the absence of Tax, CREB can activate HTLV-1 LTR expression
only if phosphorylated by PKA, another member of the family, namely CREB2, can markedly
activate the viral LTR without phosphorylation and can mediate a much stronger activation
of the viral LTR by Tax than CREB does [94, 96]. Interestingly, mutant models disrupting Tax
activation of the CREB protein resulted in the preferential immortalization of CD8+ lympho‐
cytes, rather than CD4+ lymphocytes, whereas the disruption of Tax interaction with CBP did
not affect lymphocyte immortalization [97].
5.6. Lymphoma
Lymphomas are haematological malignancies of the lymphoid system. Deregulated gene
expression is a hallmark of cancer and is well documented in B-cell lymphomas [98]. B cells
are particularly susceptible to malignant transformation since the mechanisms involved in
antibody diversification can cause chromosomal translocations and oncogenic mutations. B-
cell lymphomas include Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (B-NHL). B-
NHL consists of a heterogeneous group of diseases whose pathogenesis is associated with
multiple genetic lesions affecting oncogenes and tumour-suppressor genes and whose
treatment is related to the different grade of malignancy. The most common type of B-NHL is
represented by the diffuse large B-cell lymphoma (DLBCL), which generally arises as a clinical
evolution of the follicular lymphoma (FL). A number of papers have demonstrated the
involvement of CREB family members in the pathogenesis of lymphoma. It has been previ‐
ously found that CREB acts as a positive regulator of the translocated BCL-2 allele in FLs with
the t(14;18) translocation [60] and that the high constitutive expression of ATF-3 is linked to
the viability of Hodgkin/Reed-Sternberg cells and, thus, considered as a molecular hallmark
of classical HL [99]. More recently, a number of studies have disclosed the implication of the
HAT proteins CBP and p300 as tumour suppressors in B-cell neoplasms [100-102]. Neverthe‐
less, the various mechanisms through which each of these cofactors specifically contributes to
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lymphomagenesis are still to be elucidated. As before mentioned, CBP and p300 function as
co-activators of transcription factors and acetylate proteins relevant to lymphomagenesis such
as p53, NF-κB, Bcl-6 and Hsp90 [100, 103, 104]. In particular, p300 acts as a co-activator of NF-
κB, activates p53 but attenuates Hsp90 chaperone functions and, moreover, transcriptional
repressor BCL-6 is frequently translocated and hyper-mutated in DLBCL where it results
inversely correlated with p300 [100]. Importantly, de-acetylated Hsp90 represses p53 but
maintains BCL-6 expression, which suppresses p300 and its essential cofactor BAT3, which is
necessary for p53 acetylation and activation. Somatic heterozygous mutations or deletions of
the CREBBP locus occur in more than the 50% of DLBCL and the 32% of FL cases, whereas
EP300 mutations occur in the 10% of DLBCLs. All cases seem to have in common the disruption
of the HAT catalytic domain, and the resulting truncated or mutant proteins may have
dominant negative or gain of function properties, or may simply result in a reduced dosage
of histone acetyltransferases. Structural alterations inactivating CREBBP and, less often, EP300
have been recently documented and linked to the pathogenesis of both most common types
of B-NHL [102]. According to Pasqualucci et al. [102] point mutations at the HAT coding
domain of CREBBP and EP300 result in specific defects in acetylation-mediated inactivation
of the Bcl-6 oncoprotein and activation of the p53 tumour-suppressor, representing major
pathogenetic mechanisms shared by the most common forms of B-NHL. Suppression of p300
either through Bcl-6 or inactivating mutations plays a key role in DLBCL. In fact, treatment of
DLBCL cells with Bcl-6 inhibitors leads to p300 protein expression and acetyltransferase
activity with subsequent acetylation of p53 (which induces p53 transcriptional functions) and
Hsp90 (which suppresses Hsp90 chaperone activity) [100]. Moreover, the combination of Bcl-6
and histone deacetylase inhibitors (HDACI) leads to even higher p300 activity and synergistic
killing of lymphoma cells in vitro and in vivo [100]. Interestingly, the direct effect of HDACI on
non-histone proteins as DNA binding transcriptional factors (NF-κB, p53, CREB, GATA, c-
myc, Bcl-6, E2F, IRF) can also affect cell growth and differentiation [101]. Furthermore, in light
of HDACI effects on cell cycle regulatory molecules (Cyclin D1, p21 and p27) there is enough
evidence that indicates these novel pleiotropic drugs as promising compounds for the
treatment of B- and even T-cell malignancies in addition to conventional chemotherapy [105].
5.7. Multiple myeloma
Multiple myeloma (MM), also known as plasma cell myeloma or Kahler's disease, is a B-cell
malignancy characterized by the accumulation in the bone marrow of plasma cells with a low
proliferation index and an extended life span. Most cases of myeloma also feature the pro‐
duction of a paraprotein, an abnormal antibody that can cause kidney problems. MM cell lines
as well as de novo MM cells express multiple anti-apoptotic proteins, often do not encode
functional p53 and frequently contain a dysregulated Akt pathway [104-107]. A number of
factors related to MM cell growth and survival and linked to CREB family members have been
identified [108]. Among these factors, the myeloid cell leukaemia-1 (Mcl-1) protein, an anti-
apoptotic member of the Bcl-2 family, has been considered as a critical regulator of MM cell
survival and proposed as an attractive therapeutic target [108]. Mcl-1 is an immediate early
gene activated in response to GM-CSF and IL-3. It has been previously reported that Mcl-1
activation can occur in dependence of the PI3K/Akt pathway through a transcription factor
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complex containing CREB [109]. Recent reports have demonstrated that Mcl-1 specific down-
regulation or repression is able to initiate apoptosis in MM [110]. To this end, proteasome
inhibitors like bortezomib have been used though with contrasting results. In fact, it has been
shown that accumulated and cleaved Mcl-1 products by proteasome inhibition have either a
pro- or an anti-apoptotic function. In particular, Hu et al. [111] have investigated the role of
endoplasmic reticulum unfolded protein response (UPR) in order to unravel the mechanisms
underlying Mcl-1 accumulation following treatment with proteasome inhibitors, discovering
the enhanced translation of ATF-4, an important effector of UPR, upon proteasome inhibition,
and indicating ATF-4 as responsible for bortezomib resistance of MM [111]. Besides Mcl-1,
novel factors are being identified as important players in the pathogenesis of MM. Recent
studies have suggested that X-box–binding protein 1 (XBP1), a bZIP transcription factor of the
CREB/ATF family, has an important role in the survival of MM cells [112]. XBP1 is required
for B lymphocyte terminal differentiation to plasma cells and is essential for immunoglobulin
secretion. Abundant or deregulated expression of XBP1 has been detected in MM cells [113,
114] and in hepatocellular carcinomas [115]. Due to the production of abundant immunoglo‐
bulins and cytokines, MM cells must be able to survive under conditions of chronic ER stress
involving UPR and including constitutive activation of the ER-located transmembrane kinase/
endoribonuclease (RNase) protein IRE1α-XBP1 pathway. This pathway, implicated in the
proliferation and survival of MM cells, has been considered as a prognostic factor [116] and,
moreover, as a possible target of chemo/immunotherapy [114, 117]. A growing body of
evidence attributes a pathogenetic role to several microRNAs (miRNA) resulting up-regulated
in MM and targeting p/CAF, a positive regulator of p53 [118]. Other authors have indicated a
possible role of CREB family members in IL-6-mediated effects on myeloma cell growth and
survival [119].
6. Concluding remarks
CREB/ATF family is a growing family of transcription factors involved in a number of
physiological and pathological processes. Day by day, new family members are being
identified for their primary role in normal or aberrant haematopoiesis and proposed as
therapeutic targets of anticancer drugs [112]. In fact, by regulating gene expression, transcrip‐
tion factors are often the final mediators of such central processes as proliferation, survival,
self-renewal and invasion. Based on these effects, it is conceivable that inhibition of transcrip‐
tion factors can revert the malignant behaviour of many tumour types and can potentially
achieve a very high therapeutic index [86]. Actually, in light of its important role in the
pathogenesis of leukaemia, CREB has been indicated as a potential prognostic marker of
disease progression in AML and a molecular target for future treatment of leukaemia. In
addition, CREB has also been implicated in many solid tumours including hepatocellular
carcinoma, osteosarcoma, lung adenocarcinoma, melanoma and lymphoma [46]. Indeed, since
CREB overexpression results in a poor prognosis for the patient, the regulation of CREB activity
might represent a useful strategy to treat solid tumours like prostate, breast and lung cancer,
as well as haematological malignancies like AML and lymphoma. However, a key question
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concerns whether the activation of CREB (or other transcription factors) seen in cancer cells is
directly driving the cell malignant phenotype, or whether it is merely a by-product of activation
of one of the upstream pathways or only a partner in a more complex scenario. This is a crucial
point, since CREB would represent a good molecular target only if it were a main player in the
specific tumour biology. Unfortunately, clinical and experimental evidences suggest that
several functionally cooperating genetic alterations, including chromosomal translocations,
lead to the expression of fusion proteins that play a key role in the pathogenesis of the
leukaemia phenotype. CREB itself can promote cellular transformation as a fusion protein or
by cooperating with other oncogenes or transcription factors. Furthermore, due to the
recruitment of chromatin modulating mechanisms in the transforming activity of leukemo‐
genic factors, transcriptional therapies aimed at inhibiting DNA methyltransferases, histone
deacetylases or acetyltransferases, like CBP and p300, are emerging as new frontiers for cancer
treatment. Unlike HDACI, which have been used in several phase I/II clinical trials, HAT
inhibitors have been less extensively investigated for their potential use in cancer therapy.
Indeed, interesting results obtained with clinical treatment of solid tumours [120] suggest that
p300 inhibition may be a promising anticancer approach. To overcome the numerous side
effects and the mostly transient clinical responses exerted by epigenetic compounds used as a
single treatment [121], combinatorial therapy involving epigenetic agents together with
conventional or targeted agents is increasingly seen as a more attractive opportunity. There‐
fore, further preclinical investigations aimed at better dissecting epigenetic mechanisms
driving induction, maintenance and potential reversibility of the leukaemia state are welcome
and functional to select the most potent drugs and combinations and to develop more efficient
and long-lasting targeted therapeutic strategies. We hope to have contributed with this chapter
to make the state of the art on the role of CREB in leukaemia and lymphoma neoplasms in
order to allow further steps moving ahead from bench to bedside.
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